mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial

BACKGROUND: The aim of this non-randomized single-center phase II trial was to prospectively assess the clinical efficacy of triplet chemotherapy with modified 5-fluorouracil, folinic acid, oxaliplatin, and irinotecan (mFOLFOXIRI) plus bevacizumab as conversion therapy for initially unresectable rat...

Descripción completa

Detalles Bibliográficos

Autores principales:	Shen, Cailu, Hu, Huabin, Cai, Yue, Ling, Jiayu, Zhang, Jianwei, Wu, Zehua, Xie, Xiaoyu, Huang, Meijin, Wang, Hui, Kang, Liang, Lan, Ping, Wu, Xiaojian, Liu, Guangjian, Wan, Yunle, Zhou, Zhiyang, Huang, Yan, Li, Fangqian, Wang, Huaiming, Ma, Tenghui, Luo, Shuangling, Cai, Yonghua, Shi, Lishuo, Deng, Yanhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8908129/ https://www.ncbi.nlm.nih.gov/pubmed/35280386 http://dx.doi.org/10.21037/atm-21-6731